Clinical Autonomic Research

, Volume 16, Issue 6, pp 390–395 | Cite as

Treatment of postural tachycardia syndrome: a comparison of octreotide and midodrine

  • Robert D. Hoeldtke
  • Kimberly D. Bryner
  • Martin E. Hoeldtke
  • Gerald Hobbs


We assessed the potency of octreotide and midodrine, and their combination, in the treatment of the postural tachycardia syndrome (POTS) and orthostatic intolerance (OI). Nine patients with POTS and six patients with OI stood for up to 1 hour while their HR and BP were monitored. Patients received on separate days, midodrine 10 mg 1 hour before testing, octreotide 0.9 µg/kg 8 minutes before testing or combination therapy. Standing time in the patients with POTS was 41.2 ± 8.4 minutes and not improved by midodrine or octreotide, but increased to 56.3 ± 2.7 (P < 0.01) minutes following combination therapy. The standing heart rate in POTS, 114 ± 0.7 bpm, was suppressed by midodrine 92.8 ± 0.7 (P < 0.001), octreotide 90.6 ± 0.78 (P < 0.001), and combination therapy 84.7 ± 0.7 (P < 0.001). Combination therapy was better than monotherapy (P < 0.001) but only for the first 10 minutes of standing.

Standing time of 36.3 ± 3.5 minutes in the patients with OI improved with midodrine, octreotide and combination therapy (55.5 ± 3.1, 56.5 ± 3.5, and 56.6 ± 3.3, respectively, P < 0.05 for each). Standing heart rate in OI was 100 ± .76 bpm; following midodrine it was 80.3 ± .69 (P < 0.05), following octreotide it was 84.8 ± .86, and following combination therapy it was 71.2 ± .9 (P < 0.01). The RR interval versus time area under the curve (The Orthostatic Index) was 21.1 ± 4 in patients with OI. After midodrine it was 41.4 ± 3.5 (P < 0.01), after octreotide 40.3 ± 3.8 (P < 0.01) and after the combination it was 47.3 ± 4.6 (P < 0.001).

Midodrine and octreotide suppressed tachycardia in POTS and improved standing times in OI. The two drugs had similar potencies; combination therapy was not significantly better than monotherapy.


postural tachycardia orthostatic therapy octreotide and midodrine autonomic nervous system 


  1. 1.
    Al-Shekhlee A, Lindenberg JR, Hachwi RN, Chelimsky TC (2005) The value of autonomic testing in postural tachycardia syndrome. Clin Auton Res 15:219–222PubMedCrossRefGoogle Scholar
  2. 2.
    Benrud-Larson LM, Dewar MS, Sandroni P, Rummans TA, Haythornthwaite JA, Low PA (2002) Quality of life in patients with postural tachycardia syndrome. Mayo Clin Proc 77:531–537PubMedCrossRefGoogle Scholar
  3. 3.
    Gordon VM, Opfer-Gehrking TL, Novak V, Low PA (2000) Hemodynamic and symptomatic effects of acute interventions on tilt in patients with postural tachycardia syndrome. Clin Auton Res 10:29–33PubMedCrossRefGoogle Scholar
  4. 4.
    Harrell FE Jr (2001) Regression modeling strategies. Springer, New York, pp 413–432Google Scholar
  5. 5.
    Hoeldtke RD, Davis KM (1991) The orthostatic tachycardia syndrome: evaluation of autonomic function and treatment with octreotide and ergot alkaloids. J Clin Endocrinol Metab 73:132–139PubMedCrossRefGoogle Scholar
  6. 6.
    Hoeldtke RD, Davis KM, Joseph J, Gonzales R, Panidis IP, Friedman AC (1991) Hemodynamic effects of octreotide in patients with autonomic neuropathy. Circulation 84:168–176PubMedGoogle Scholar
  7. 7.
    Hoeldtke RD, Horvath GG, Bryner KD, Hobbs GR (1998) Treatment of orthostatic hypotension with midodrine and octreotide. J Clin Endocrinol Metab 83:339–343PubMedCrossRefGoogle Scholar
  8. 8.
    Julu PO, Cooer VL, Hansen S, Hainsworth R (2003) Cardiovascular regulation in the period preceding vasovagal syncope in conscious humans. J Physiol 549:299–311PubMedCrossRefGoogle Scholar
  9. 9.
    Low PA, Gilden JL, Freeman R, Sheng K, McElligott MA (1997) Midodrine Study Group. Efficacy of midodrine vs. placebo in neurogenic orthostatic hypotension. JAMA 277:1046–1051PubMedCrossRefGoogle Scholar
  10. 10.
    Razzore P, Colao A, Baldelli R, Gaia D, Marzullo P, Ferretti E (1999) Comparison of six months therapy with octreotide versus lanreotide in acromegalic patients: a retrospective study. Clin Endocrinol (Oxf) 51:159–164CrossRefGoogle Scholar
  11. 11.
    Stewart JM, McLeod KJ, Sanyal S, Herzberg G, Montgomery LD (2004) Relation of postural vasovagal syncope to splanchnic hypervolemia in adolescents. Circulation 100:2575CrossRefGoogle Scholar
  12. 12.
    Stewart JM, Medow MS, Glover JL, Montgomery L (2006) Persistent splanchnic hyperemia during upright tilt in postural tachycardia syndrome. Am J Physiol Heart Circ Physiol 290:H665–H673PubMedCrossRefGoogle Scholar
  13. 13.
    Streeten DHP, Anderson GH (1992) Delayed orthostatic intolerance. Arch Intern Med 152:1066–1072PubMedCrossRefGoogle Scholar
  14. 14.
    Streeten DHP, Anderson GH, Richardson R, Thomas FD (1988) Abnormal orthostatic changes in blood pressure and heart rate in subjects with intact sympathetic nervous function: evidence for excessive venous pooling. J Lab Clin Med 111:326–335PubMedGoogle Scholar
  15. 15.
    Tani H, Singer W, McPhee BR, Opfer-Gehrking TL, Haruma K, Kajiyama G et al. (2000) Splanchnic-mesenteric capacitance bed in the postural tachycardia syndrome (POTS). Auton Neurosci 86:107–113PubMedCrossRefGoogle Scholar
  16. 16.
    Winer BJ (1979) Statistical principles and experimental design, 2nd edn. McGraw Hill, New York, pp 309–603Google Scholar

Copyright information

© Steinkopff Verlag Darmstadt 2006

Authors and Affiliations

  • Robert D. Hoeldtke
    • 1
  • Kimberly D. Bryner
    • 1
  • Martin E. Hoeldtke
    • 1
  • Gerald Hobbs
    • 2
  1. 1.Dept. of MedicineWest Virginia UniversityMorgantownUSA
  2. 2.Dept. of Community Medicine and StatisticsWest Virginia UniversityMorgantownUSA

Personalised recommendations